(Clarification of the day of the week in the first paragraph: Thursday evening rpt. Thursday evening)
MAINZ (dpa-AFX) – The pharmaceutical supplier SCHOTT Pharma continues to struggle with market uncertainty. The outlook for the still young financial year 2025/26 is correspondingly cautious and falls short of market expectations. 2026 will be “a transitional year in which we will operate in a challenging market environment and prepare for the next phase of growth,” said company boss Andreas Reisse, according to an announcement on Thursday evening. The share price fell after hours.
In the 2026 financial year, which has been running since October, revenue is expected to grow by 2 to 5 percent after adjusting for currency effects, it said. The Mainz company assumes the profit margin before interest, taxes, depreciation and amortization (Ebitda margin) to be around 27 percent. However, according to the market, an increase in sales of a good 8 percent and an operating margin of almost 29 percent are expected.
The company also backtracked on its medium-term outlook. An average annual sales growth of 6 to 8 percent should be achieved for the financial years 2027 to 2029. The operating margin should move towards 30 percent. Most recently, an average annual sales increase of more than 10 percent and a margin in the lower 30s percent range were expected.
“The headwind will continue in the short term, particularly in the Drug Delivery Systems segment,” explained Schott Pharma boss Reisse. The changed market assessment of an important customer is leading to lower demand for glass syringes.
With a view to the past 2024/25 financial year, based on preliminary results, the company achieved a currency-adjusted increase in sales of 5.8 percent to a good 986 million euros. The company thus roughly achieved the previously lowered forecast of internal revenue growth of around 6.0 percent.
The operating margin climbed from 26.9 to 28.4 percent in 2024/25 after adjusting for currency effects. This corresponds to earnings before interest, taxes, depreciation and amortization of a good 280 million euros. The detailed figures for the past financial year will follow in a week on December 11th.
In the evening, the shares on the Tradegate trading platform fell by around two and a half percent to a good 18 euros compared to the Xetra closing. In the main Xetra business there is a risk of a record low on Friday, below the previous low of 17.90 euros from November.
The Mainz-based specialty glass manufacturer Schott listed its pharmaceutical division on the stock exchange in September 2023 at an issue price of 27 euros per paper. By the beginning of 2024 it rose to a good 43 euros, and the downward trend has continued since then./mis/men/tih/stk
Selected leverage products on SCHOTT Pharma
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on SCHOTT Pharma
The leverage must be between 2 and 20
Advertising